anti-Pappalysin 2 (PAPPA2) Antibodies

Mouse (Murine) Pappalysin 2 (PAPPA2) interaction partners

1. Pappa2 deletion is associated with bone resorption.

2. This review evaluates the current data concerning PAPP-A2 function, and particularly the effect of PAPP-A2 mutation on growth.

3. Locally-produced Pappa2 in osteoblasts, epiphysis, and metaphysis, is required for normal postnatal bone growth.

4. Despite a dramatic disruption of the balance between circulating IGF-I, IGFBP-3 and -5, we found no effects of Pappa2 deletion on glucose metabolism, weight gain or adiposity on a high-fat diet.

5. Pappa2 deletion had no effect on female reproduction and subtle effects on male fertility.

6. Pappa2 is responsible for the effects of the previously-identified QTL, demonstrating that natural variation in the Pappa2 gene contributes to variation in postnatal growth in mice

7. investigation of biological role of PAPP-A2 using knockout mice, heterozygotes, primary fibroblasts: The most striking phenotype of PAPP-A2 KO mice was postnatal growth retardation. PAPP-A2 KO mice were fertile, but exhibited compromised fecundity.

8. Elevated PAPPA2 levels are a consequence rather than a cause of pregnancy complications.

9. The refinement of the target region to four genes and the finding that the QTL affects IGFBP-5 levels suggest that PAPPA2 may be involved with normal postnatal growth

10. Pappa2 expression also shows specific localization within the mouse embryo and therefore may play roles in fetal development, independent of its action in the placenta

Human Pappalysin 2 (PAPPA2) interaction partners

1. PAPP-A2 mutation is associated with idiopathic short stature.

2. The findings suggest a possible pathophysiological link between the development of Fetal growth restriction and the expression of PAPPA, PAPPA2 and PLAC-1.

3. Pregnancy associated plasma protein-A (PAPP-A) appears to be a potentially useful biomarker for short-term risk stratification of patients presenting with chest pain of ischemic origin (Review).

4. PAPP-A2 is increased in Hemodialysis patients and interacts with PAPP-A on patients prognosis.

5. This review evaluates the current data concerning PAPP-A2 function, and particularly the effect of PAPP-A2 mutation on growth.

6. These patients provide important insights into the regulation of longitudinal growth in humans, documenting the critical role of PAPP-A2 in releasing IGF-I from its binding proteins.

7. Short-term treatment with progressive doses of rhIGF1 (recombinant human insulin-like growth factor-1) improved growth in two siblings with deficiency of PAPP-A2 (pregnancy-associated plasma protein-A2) [due to a homozygous loss-of-function frameshift mutation in exon 3 of the PAPP-A2 gene (p.D643fs25*)] that resulted in postnatal growth failure due to resulting decrease in IGF1 bioavailability. [CASE REPORT]

8. in situ hybridization (ISH) and immunohistochemistry (IHC) were employed to examine the spatial and temporal expression of PAPPA2 in the human fetomaternal interface.

9. PAPP-A2 is differentially expressed in different trophoblast populations and shows strong down regulation in the mid second trimester in chorionic villous samples.

10. overexpression in Down syndrome from placental mRNA to maternal serum protein

11. The association between this PAPPA2 single nucleotide polymorphism and developmental dysplasia of the hip was evaluated.

12. The upregulation of PAPP-A2 observed in preeclampsia at term occurs early in pregnancy, before the symptoms develop.

13. PAPPA2 may be upregulated in severe pre-eclampsia and, functionally, this may be mediated via increased placental hypoxia known to occur with this pregnancy disorder.

14. The existence of this assay will enable an assessment of the biomarker potential of PAPP-A2 in pre-eclampsia as well as other clinical conditions.

15. Association of a single nucleotide polymorphism in pregnancy-associated plasma protein-A2 with developmental dysplasia of the hip

16. factors previously known to be highly expressed in preeclamptic placentae (PGE2 and TNF-alpha), contribute to the upregulation of PAPPA2. results are consistent with the hypothesis that PAPPA2 is upregulated as a consequence of placental pathology

17. Circulating IGFBP-5 is proteolyzed by PAPP-A2 during pregnancy, resulting in increased IGF bioavailability, which may have important consequences for the development of the fetus and/or the well-being of the mother.

18. Seven placental transcripts characterize HELLP-syndrome.

19. PAPP-A2 in syncytiotrophoblast cells was dramatically increased in pre-eclampsia. Maternal serum concentrations of PAPP-A2 were also significantly elevated in pre-eclampsia as compared with uncomplicated pregnancy.

20. Preeclampsia involves changes in the gene expression of PAPPA2 in placental cytotrophoblasts.

Cow (Bovine) Pappalysin 2 (PAPPA2) interaction partners

1. Variants in the pregnancy-associated plasma protein-A2 gene on Bos taurus autosome 16 are associated with daughter calving ease and productive life in Holstein cattle.

Zebrafish Pappalysin 2 (PAPPA2) interaction partners

1. Papp-a2 modulates Bmp and Notch signaling by independent mechanisms in zebrafish embryos to control cranial cartilage development and angiogenesis.